First Bancshares Upgraded by Zacks Investment Research

First Bancshares has 3 insider buys in recent days after announcing the purchase of Alabama Bank. Zacks upgraded the stock to a Buy rating today.

First Bancshares stock was upgraded by analysts at Zacks Investment Research from a Hold rating to a Buy rating. They now have a $35 price target on the stock which represents 9.7% upside from the previous close of $31.90.

AMN Healthcare Services Pocket Pivot and Rising Large Players Volume

Strong technical setup with bullish sentiment from analysts. The company is also a strong seasonal play. The company was also recently ranked #11 on Fortune’s 100 Fastest Growing Companies list.

AMN Healthcare Services chart shows a beautiful setup with rising large players volume and a pocket pivot signal.

AMN Healthcare Services is also a good seasonal play. Over the next 10 weeks, AMN Healthcare Services has on average historically risen by 9.4% based on the past 15 years of stock performance. AMN Healthcare Services has risen higher in 12 of those 15 years over the next 10 week period, corresponding to a historical probability of 80%.

Intevac Company Consolidating On Rising Large Players Volume

Intevac Inc stock is consolidating as large players volume moves higher after the company reported revenue growth of 18% year-over year.

Intevac issued its earnings results on Monday, October, 30th. The company reported EPS of $0.04 for the quarter. The company beat on revenue of $26.70 million versus analysts estimates of $25.50 million.

Ur-Energy Company Gets 277 Percent Price Target From Roth Capital

Ur-Energy was given a new $2 price target by analysts at Roth Capital which represents 277.4% upside from the current price. Roth Capital has a Buy rating on the stock.

Ur-Energy has 3 Buy ratings with a consensus price target of $1.67 which represents 214.47% upside from the current price.

Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald

Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock.

Verastem is on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma. Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.

TrueBlue Company Beats as Large Players Volume Surges

TrueBlue Company beat on earnings and revenue. The company reported Q3 EPS of $0.60 versus the estimate of $0.58. Revenue also beat coming in at $660.78 million for the quarter versus the estimate of $651.91 million.

Archrock Partners Exploding Large Players Volume On Analyst Buy Rating

Archrock Partners large players volume has exploded higher as price has moved lower. This is a huge positive divergence and very bullish for the stock.

Royal Bank Of Canada reiterated its Buy rating on Archrock Partners stock and set a price target of $19 which represents 44.27% upside from the current price. I'm seeing a lot of bullish analysts actions in many oil and gas stocks.

Sofi AI Market Sentiment Gauge

Sofi AI Market Sentiment Gauge

Market is neither overbought or oversold.